Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
Titel:
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
Auteur:
Albertsson, M. Johansson, B. Friesland, S. Kadar, L. Letocha, H. Frykholm, G. Wagenius, G.